NASDAQ:ABMDABIOMED Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding ABIOMED, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $249.81 +13.79 (+5.84 %) (As of 06/5/2020 04:00 PM ET) Add Compare Share Today's Range$236.10Now: $249.81▼$251.8750-Day Range$159.54MA: $189.89▼$238.0452-Week Range$119.01Now: $249.81▼$285.77Volume600,309 shsAverage Volume484,171 shsMarket Capitalization$11.23 billionP/E Ratio56.52Dividend YieldN/ABeta0.91 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media ABIOMED, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite. It also provides Impella 5.0 and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; and Impella RP, a percutaneous catheter-based axial flow pump. In addition, the company is involved in the development of Impella 5.5 and Impella BTR that are percutaneous micro heart pumps with integrated motors and sensors; and Impella ECP pump, a device for blood flow of greater than three liters per minute. It sells its products through direct sales and clinical support personnel in the United States, Canada, Europe, and Japan. The company was founded in 1981 and is headquartered in Danvers, Massachusetts.Read More Beat the Market (BTM) Rank™ 2.1 Analyst's Opinion Consensus RatingABIOMED has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 3 buy ratings, 4 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $193.00, ABIOMED has a potential downside of 22.7% from its current price of $249.81.Amount of Analyst CoverageABIOMED has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.6 Community Rank Outperform VotesABIOMED has received 521 “outperform” votes. (Add your “outperform” vote.)Underperform VotesABIOMED has received 471 “underperform” votes. (Add your “underperform” vote.)Community SentimentABIOMED has received 52.52% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about ABIOMED and other stocks. Vote “Outperform” if you believe ABMD will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ABMD will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldABIOMED does not currently pay a dividend.Dividend GrowthABIOMED does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ABIOMED insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.40% of the stock of ABIOMED is held by insiders.Percentage Held by Institutions94.41% of the stock of ABIOMED is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for ABIOMED are expected to grow by 42.94% in the coming year, from $3.26 to $4.66 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ABIOMED is 56.52, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 16.79.Price to Earnings Ratio vs. SectorThe P/E ratio of ABIOMED is 56.52, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 23.75.Price to Earnings Growth RatioABIOMED has a PEG Ratio of 3.72. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioABIOMED has a P/B Ratio of 10.57. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 2.1Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.9 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.52 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment SectorMedical Current SymbolNASDAQ:ABMD Previous Symbol CUSIP00365410 CIK815094 Webwww.abiomed.com Phone978-646-1400Debt Debt-to-Equity RatioN/A Current Ratio4.82 Quick Ratio4.14Price-To-Earnings Trailing P/E Ratio56.52 Forward P/E Ratio76.63 P/E Growth3.72 Sales & Book Value Annual Sales$840.88 million Price / Sales13.36 Cash Flow$5.58 per share Price / Cash Flow44.76 Book Value$23.64 per share Price / Book10.57Profitability EPS (Most Recent Fiscal Year)$4.74 Net Income$203.01 million Net Margins24.14% Return on Equity18.51% Return on Assets16.31%Miscellaneous Employees1,536 Outstanding Shares44,960,000Market Cap$11.23 billion Next Earnings Date8/6/2020 (Estimated) OptionableOptionable NASDAQ:ABMD Rates by TradingView Receive ABMD News and Ratings via Email Sign-up to receive the latest news and ratings for ABMD and its competitors with MarketBeat's FREE daily newsletter. ABIOMED (NASDAQ:ABMD) Frequently Asked Questions How has ABIOMED's stock been impacted by COVID-19 (Coronavirus)? ABIOMED's stock was trading at $151.13 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ABMD shares have increased by 65.3% and is now trading at $249.81. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of ABIOMED? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ABIOMED in the last year. There are currently 1 sell rating, 4 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for ABIOMED. When is ABIOMED's next earnings date? ABIOMED is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for ABIOMED. How were ABIOMED's earnings last quarter? ABIOMED, Inc. (NASDAQ:ABMD) posted its quarterly earnings results on Thursday, April, 30th. The medical equipment provider reported $0.70 earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $0.96 by $0.26. The medical equipment provider earned $206.66 million during the quarter, compared to analyst estimates of $209.58 million. ABIOMED had a return on equity of 18.51% and a net margin of 24.14%. The firm's revenue was down .2% compared to the same quarter last year. During the same period in the prior year, the business posted $1.60 EPS. View ABIOMED's earnings history. What price target have analysts set for ABMD? 8 equities research analysts have issued 12-month target prices for ABIOMED's stock. Their forecasts range from $152.00 to $240.00. On average, they anticipate ABIOMED's share price to reach $193.00 in the next twelve months. This suggests that the stock has a possible downside of 22.7%. View analysts' price targets for ABIOMED. Has ABIOMED been receiving favorable news coverage? News headlines about ABMD stock have been trending positive this week, according to InfoTrie. The research group identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. ABIOMED earned a media sentiment score of 2.4 on InfoTrie's scale. They also gave news articles about the medical equipment provider a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news aboutABIOMED. Who are some of ABIOMED's key competitors? Some companies that are related to ABIOMED include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Becton Dickinson and (BDX), Intuitive Surgical (ISRG), Boston Scientific (BSX), Baxter International (BAX), Edwards Lifesciences (EW), DexCom (DXCM), IDEXX Laboratories (IDXX), ResMed (RMD), Teleflex (TFX), Steris (STE), Hologic (HOLX) and Masimo (MASI). View all competitors. What other stocks do shareholders of ABIOMED own? Based on aggregate information from My MarketBeat watchlists, some companies that other ABIOMED investors own include NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Align Technology (ALGN), Netflix (NFLX), Arista Networks (ANET), Square (SQ), Paypal (PYPL), salesforce.com (CRM) and Adobe (ADBE). Who are ABIOMED's key executives? ABIOMED's management team includes the following people: Mr. Michael R. Minogue, Chairman, CEO & Pres (Age 52)Dr. David M. Weber, Chief Operating Officer (Age 58)Mr. Michael G. Howley, VP & GM of Global Sales (Age 55)Mr. William J. Bolt, Exec. Officer (Age 67)Mr. Ian McLeod, VP & Corp. Controller What is ABIOMED's stock symbol? ABIOMED trades on the NASDAQ under the ticker symbol "ABMD." Who are ABIOMED's major shareholders? ABIOMED's stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (8.37%), Primecap Management Co. CA (6.49%), Wellington Management Group LLP (6.39%), Baillie Gifford & Co. (6.05%), State Street Corp (4.43%) and Brown Capital Management LLC (3.64%). Company insiders that own ABIOMED stock include Andrew J Greenfield, David M Weber, Martin P Sutter, Michael G Howley and Michael R Minogue. View institutional ownership trends for ABIOMED. Which institutional investors are selling ABIOMED stock? ABMD stock was sold by a variety of institutional investors in the last quarter, including Sands Capital Management LLC, William Blair Investment Management LLC, Franklin Resources Inc., Janus Henderson Group PLC, Primecap Management Co. CA, Morgan Stanley, Morgan Stanley, and Two Sigma Advisers LP. View insider buying and selling activity for ABIOMED. Which institutional investors are buying ABIOMED stock? ABMD stock was acquired by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Alliancebernstein L.P., BlackRock Inc., Baird Financial Group Inc., Global Thematic Partners LLC, Fred Alger Management LLC, Deutsche Bank AG, and TimesSquare Capital Management LLC. View insider buying and selling activity for ABIOMED. How do I buy shares of ABIOMED? Shares of ABMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is ABIOMED's stock price today? One share of ABMD stock can currently be purchased for approximately $249.81. How big of a company is ABIOMED? ABIOMED has a market capitalization of $11.23 billion and generates $840.88 million in revenue each year. The medical equipment provider earns $203.01 million in net income (profit) each year or $4.74 on an earnings per share basis. ABIOMED employs 1,536 workers across the globe. What is ABIOMED's official website? The official website for ABIOMED is www.abiomed.com. How can I contact ABIOMED? ABIOMED's mailing address is 22 CHERRY HILL DR, DANVERS MA, 01923. The medical equipment provider can be reached via phone at 978-646-1400 or via email at [email protected] This page was last updated on 6/6/2020 by MarketBeat.com Staff
